New Delhi [India], January 19 (ANI): The Drugs Controller General of India's (DCGI) subject expert committee (SEC) has recommended the regular market approval to Serum Institute of India and Bharat Biotech for their COVID-19 vaccines Covaxin and Covishield with conditions for the adult po
New Delhi [India], January 14 (ANI): The Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) will continue thorough review of data submitted by the Serum Institute of India (SII) and Bharat Biotech for granting full market approval to Covaxin and Covishield, sources
New Delhi [India], January 14 (ANI): Drugs Controller General of India (DCGI)'s Subject Expert Committee will review applications of Bharat Biotech and Serum Institute of India (SII) for full market approval to Covaxin and Covishield respectively on Friday, sources said.
Gaithersburg/Pune (Maryland/Maharashtra)[US/India], December 29 (ANI): Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India (SII), the world's largest vaccin
Houston [US], December 29 (ANI): Texas Children's Hospital and Baylor College of Medicine announced on Tuesday (local time) that Corbevax, a protein sub-unit COVID-19 vaccine, whose technology was created and engineered at its Center for Vaccine Development (CVD), has received Emergency Use
Hyderabad (Telangana) [India], December 28 (ANI): Drugs Controller General of India (DCGI) on Tuesday approved Dr Reddy's laboratories for the emergency-use authorisation) to manufacture and market the oral anti-viral drug Molnupiravir capsules 200mg for the treatment of adult patients with
New Delhi [India], December 28 (ANI): After reviewing all applications and data, the Subject Expert Committee (SEC), a body under India's drug regulator, has recommended granting the Emergency Use Authorization (EUA) to Serum Institute of India's COVID-19 vaccine Covovax and Corbevax vacc
New Delhi [India], December 25 (ANI): Covaxin has a proven record for safety and efficacy from all the variants of COVID-19, said Bharat Biotech after its vaccine received emergency usage approval from the Drugs Controller General of India (DCGI) for kids aged between 12-18 years.
New Delhi [India], December 25 (ANI): Bharat Biotech's COVID-19 vaccine Covaxin has received approval from the Drugs Controller General of India (DCGI) for emergency use for kids aged between 12-18 years, official sources said.
New Delhi [India], December 20 (ANI): As India is witnessing a surge in cases of "highly transmissible" Omicron variant, Hyderabad-based Bharat Biotech has submitted the phase 3 clinical trial application to the Drugs Controller General of India (DCGI) to get approval for the booster dose
Bangalore (Karnataka) [India], December 9 (ANI/BusinessWire India): Algorithmic Biologics, a deep-tech startup building algorithms for molecular programming, today announced that it has received ConformiteEuropeene (CE) Mark approval for its proprietary compressed molecular testing method ca
New Delhi [India], November 8 (ANI): The data for Bharat Biotech's Covaxin for Children, COVID-19 vaccine, is under evaluation and the process will take some more time for final approval from the Drugs Controller General of India (DCGI), sources said.